A central venous catheter (KATHeter), also known as a central line or CVC, is a long, soft, thin, hollow tube that is placed into a large vein (blood vessel). A central venous catheter differs from an intravenous (IV) catheter placed in the hand or arm (also called a “peripheral IV”). A central line is longer, with a larger tube, and is placed in a large (central) vein in the neck, upper chest or groin. This type of catheter has special benefits in that it can deliver fluids into a larger vein, and that it can stay in the body for a longer period of time than a usual, shorter IV.

Common reasons for having a central line include:

• To give IV medications over a long period of time because a large vein can tolerate an IV catheter for a longer time than a small vein. Examples of such medications are antibiotics and chemotherapy.
• To deliver IV medications as an outpatient. Compared with a shorter IV, a central venous catheter is less likely to come out of the vein and this allows patients to be more active and receive IV medications at home.
• To rapidly deliver large amounts of fluid or blood, for example when a person is in shock
• To directly measure blood pressure in a large or central vein. This can help determine how much fluid a person needs.
• To take frequent blood samples (more than once each day) without being stuck with needles many times
• To deliver nutrition directly into the blood when food or liquids cannot be given through the mouth, stomach, or intestine
• To connect a person with kidney failure to a hemodialysis machine that clears the body of wastes and extra fluid

Market Dynamics

The research and development of device like central venous catheter by the market player is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in May 2018, Pursuit Vascular Inc., a medical device company, announced that the US Food and Drug Administration (FDA) had granted clearance for a broader indication for ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infections (CLABSI) in hemodialysis patients with central venous catheters (CVCs).

Moreover, increasing prevalence of cardiovascular disease in the U.S. is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in January 2021, Heart Disease and Strokes Statistics, the U.S. age-adjusted death rate attributable to cardiovascular disease (CVD), based on 2018 data, on average, someone dies of CVD every 36 seconds. There are 2,380 deaths from CVD each day, based on 2018 data, whereas someone dies of a stroke every 3 minutes and 33 seconds in the U.S. There are about 405 deaths from stroke each day, based on 2018 data.

Key features of the study:

• This report provides an in-depth analysis of the U.S. central venous catheter market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2024 – 2031, considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the U.S. central venous catheter market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include AngioDynamics, Inc, C.R. Bard, Inc, Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc, Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc.,ICU Medical, Inc.,Theragenics Corporation, Becton, Dickinson and Company,icumedical, Polymedicure, Lepu Medical Technology (Beijing) Co.,Ltd., VOGT MEDICAL, Gilead Sciences, Inc and ZOLL Medical Corporation
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future drug launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The U.S. central venous catheter market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. central venous catheter market

Detailed Segmentation:

• U.S. Central Venous Catheter Market, By Product Type:
• Peripherally Inserted Central Catheters (PICC)
• Implantable Ports
• Tunneled Central Venous Catheter
• Non-tunneled Central Venous Catheter
• U.S. Central Venous Catheter Market, By Design:
• Single Lumen
• Double Lumen
• Multi Lumen
• U.S. Central Venous Catheter Market, By Composition:
• Polyurethane
• Polyethylene
• Silicon
• U.S. Central Venous Catheter Market, By Procedure:
• • Cardiovascular Procedure
  • Chemotherapy Procedure
  • Dialysis Procedure
• U.S. Central Venous Catheter Market, By End User:
  • Hospital
  • Ambulatory Surgical Centers
  • Specialty Clinics
• Company Profiles
  • AngioDynamics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • R. Bard, Inc.
  • Teleflex Incorporated
  • Braun Melsungen AG
  • Medtronic Plc
  • Vygon Ltd.
  • Cook Medical, Inc.
  • Argon Medical Devices, Inc.
  • ICU Medical, Inc.
  • Theragenics Corporation
  • Becton, Dickinson and Company
  • icumedical
  • Polymedicure
  • Lepu Medical Technology (Beijing) Co.,Ltd.
  • VOGT MEDICAL
  • Gilead Sciences, Inc
  • ZOLL Medical Corporation

 “*” marked represents similar segmentation in other categories in the respective section.